Our Blueprint

Our Blueprint is a thought leadership platform to share more about our areas of focus, our team’s expertise, and our goals for the future.

Read posts

Honoring Rare Disease Day: An annual movement supported by a daily commitment to improving patients’ lives

February 29, 2024

Since our company’s inception in 2011, we’ve worked to bring innovative medicines to patients in need of new treatment options, including those living with a…

Read more

Finding patterns in symptom data to help improve patient care: Building the SM profile with outcomes research and real-world evidence

January 15, 2024

Every disease has a story, including its natural history, clinical presentation, signs and symptoms, and effect on a person’s quality of life. While these factors…

Read more

“When the hoofbeats are zebras”: Using AI to improve SM diagnosis times

December 15, 2023

There is an old adage in medicine: “When you hear hoofbeats, think horses, not zebras.” In other words, think of common illnesses when evaluating patients…

Read more

An enduring work of art that conveys…

December 11, 2023

Sharing dinner every night with family. Adapting to a new culture. Recovering from the unimaginable with the help of your dog. So often, it is…

Read more

Women’s leadership award puts the spotlight on Blueprint’s intentional approach to business and culture

November 2, 2023

The Women’s Edge, a non-profit dedicated to advancing women in leadership, and the Boston Globe Magazine have named Blueprint Medicines one of the Top 100…

Read more

It’s SMthing: Using patient insights and online search patterns to connect more people to information about systemic mastocytosis

August 16, 2023

We knew that a pattern existed, but no one was seeing it. Occurring in about 32,000 people in the United States, systemic mastocytosis is a…

Read more

This is Our Blueprint

June 5, 2023

Precision medicine is a term that is used a lot in the biotech industry. Precision medicine hopes to deliver dramatically better and safer treatments by…

Read more

Recognition of Blueprint Medicines’ Intentional
Work to Diversify Our Leadership

May 8, 2023

Years of intentional work to diversify Blueprint Medicines’ leadership is being recognized. A report from the Eos Foundation found Blueprint Medicines was one of the…

Read more

The importance of Rare Disease Day

February 28, 2023

Rare Disease Day is a very important reminder of the struggles faced by those living with rare conditions across the world, including their family and…

Read more

International Mastocytosis and Mast Cell Diseases Awareness Day 2022

October 17, 2022

Since early in our company’s history, we’ve been deeply committed to advancing care for systemic mastocytosis as we aim to address unmet patient needs. This…

Read more

AACR Annual Meeting 2022: Showcasing our Precision Therapy Pipeline

April 8, 2022

At the American Association for Cancer Research (AACR) Annual Meeting 2022, we’re presenting new clinical and preclinical data for multiple programs across our precision therapy…

Read more

Implementing a meaningful and sustainable equity, diversity and inclusion strategy

January 18, 2022

Originally published on MassBio.org December 20, 2021 At Blueprint Medicines, we’ve been committed to equity, diversity, and inclusion (ED&I) since our company’s founding in 2011.…

Read more

The right moment for thoughtful transition of leadership at Blueprint Medicines

January 12, 2022

Last week, we announced that Jeff Albers, our Chief Executive Officer (CEO), has decided to step down and move into the position of Executive Chairman,…

Read more

Blueprint’s Biomarker Testing Program: KIT D816V Test Available for Eligible U.S. Patients Suspected of Having Systemic Mastocytosis

November 22, 2021

Receiving a timely diagnosis is difficult for many patients living with a rare disease. These challenges are particularly significant for systemic mastocytosis (SM), a rare…

Read more

Female Leaders at Blueprint Medicines Bringing
Leadership across the Life Sciences Industry

October 22, 2021

At Blueprint Medicines, we believe diversity is a core strength of our business.  By drawing upon a range of backgrounds, experiences and perspectives, we strengthen…

Read more

Our first decade of innovation in precision medicine

April 21, 2021

This month marks 10 years since Blueprint Medicines began operations, and it’s a natural time to celebrate the science, patients and people who have made…

Read more

Joining Other Precision Medicine Stakeholders to Develop United Language for Testing

June 11, 2020

With more biomarker-targeted therapies becoming available, patient advocacy groups have increasingly talked about the challenge of confusing terminology for cancer testing. In March 2019, my…

Read more

ASCO 2019: Advancing Cancer Treatment with Precision Therapies

May 31, 2019

At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, a key focus will be precision therapy – targeting genetic drivers of cancer with…

Read more

Blueprint Medicines Recognizes International FOP Awareness Day

April 23, 2019

Letter from Marion Dorsch, Chief Scientific Officer Today, Blueprint Medicines stands with the patient community and recognizes International Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day. In…

Read more

How Our Research Platform Helped Accelerate the Discovery of BLU-667

April 10, 2019

Discovering potent and selective kinase drugs is a challenging endeavor. Setting up and completing a screen of a new drug target against a compound library…

Read more

Blueprint Medicines Introduces The Lens

January 2, 2019

Welcome to The Lens, our new thought leadership platform to share our team’s expertise in precision medicine. We are pioneers in this rapidly evolving field,…

Read more